Overview

Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19

Status:
Terminated
Trial end date:
2021-06-02
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to assess the safety and toxicity profile of the combination of famotidine and oral n-acetyl cysteine in adult outpatients with newly diagnosed SARS-CoV-2 infection.
Phase:
Phase 1
Details
Lead Sponsor:
Prisma Health-Upstate
Collaborator:
Clemson University
Treatments:
Acetylcysteine
Famotidine
N-monoacetylcystine